U-CARS 2022

AGENDA

Thursday - March 24, 2022 

*All presentations were recorded during the live event and are available to view in the agenda below.

(All times MST)

8.45-9.45am

View CVRx recording HERE

Industry Theater - CVRx: Barostim: Autonomic Modulation for Heart Failure (Non-CME)
Rahul Doshi, (HonorHealth), Richard Shelton, (U of U/ SLC VA), Christina Economides, (PIH Good Samaritan Hospital), Luanda Grazette, (U of Miami)

9.45-10.45am

View AstraZeneca recording HERE

Industry Theater - AstraZeneca: A Treatment Option for Patients with HFrEF (Non-CME)
Ted Okerson, MD, FACP, FACE, Senior Field Physician, Cardiovascular, Renal, and Metabolism

10.45-11.45am

View Abiomed recording HERE

Industry Theater – Abiomed: Taking the Failure out of Heart Failure: Future of HF Recovery (Non-CME)
Jane E. Wilcox, MD, MSc, Northwestern Medicine
 

Noon-1.30pm

View Sessions 1- 3 & Keynote address recordings HERE

Session 1: What is Good Enough Myocardial Repair, Recovery or Remission in Chronic HF?

Chairs: James Fang, MD (U of U), Karen May-Newman, PhD, (San Diego State U) and Robin Shaw, MD/PhD (U of U)

1. Clinical perspective. Clyde Yancy, MD, Northwestern
2. Biomedical engineering perspective. James Antaki, PhD, Cornell
3. Basic science perspective. Florian Weinberger, MD, University of Hamburg, Germany

(20 min talks + 10min discussion each) 

1.30 – 2.30pm

Keynote address - Recovery from What?

Lynne Warner Stevenson, MD, Vanderbilt University
(45 min talk followed by 15 min discussion)

2.30 - 2.45pm Break

2.45-4.50pm

Session 2: Innovation in Heart Failure & Myocardial Recovery

Chairs:  Kirk Knowlton, MD (Intermountain), TingTing Hong, PhD (U of Utah/CVRTI) and Omar Wever Pinzon, MD (U of U)

1. PKG takes a left turn – new stuff this kinase can do. David Kass, MD, Johns Hopkins
2. Exploiting cardiac cell surface glycoproteins for precision medicine. Rebekah Gundry, PhD, U of Nebraska
3. Transcriptional Regulation of Cardiomyocyte Renewal: From Mechanism to Therapeutics. Hesham Sadek, MD/PhD, UTSW
4. Immaturity of cardiomyocytes and change of bone marrow induce heart failure. Issei Komuro, MD, PhD, University of Tokyo, Japan
5. The inflammation hypothesis and HF therapeutics: how does a real comeback look like? Antonio Abbate, MD, VCU

(18 min talks + 6 min discussion each) 

4.50-6.30pm

Session 3: Innovation in Myocardial Metabolism

Chairs: Jared Rutter, PhD (U of U/HHMI), Sihem Boudina, PhD (U of U) and Scott Summers, PhD (U of U)

1. Mitochondrial metabolites in cardiac ischemia reperfusion injury. Michael P. Murphy, PhD, Cambridge, UK
2. Novel Mitochondrial Mechanisms. Rong Tian, MD, University of Washington/Seattle
3. Cardiac mitochondrial Ca2+: how it is regulated and its role in cardiovascular function and disease. Elizabeth Murphy, PhD, NHLBI / NIH Intramural Research Program
4. Glucose Metabolism and Heart Failure. Dale Abel, MD/PhD, UCLA

(18 min talks + 6min discussion each) 

Friday - March 25, 2022 

(All times MST)  

8.00 - 9.30am

Virtual Poster Presentations (Non-CME)

9.45-10.45am

View Kiniksa recording HERE

Industry Theater – Kiniksa: Treating Recurrent Pericarditis and Preventing Recurrence (Non-CME)

John J. Ryan, MD, Director, Dyspnea & Pulmonary Hypertension Centers Director, Cardiovascular Medicine Unit
(U of U)

10.45-11.45am

View Abbott Recording HERE

Industry Theater – Abbott: Innovation in Mechanical Circulatory Support; Beyond Technology (Non-CME)

Robert L. Kormos, MD, FAHA, FRCS(C), FACS - DVP Global Affairs, Heart Failure (Abbott Laboratories)

12.00 (Noon) – 2.00pm

View Featured Oral Presentation recordings HERE

Session 4: Featured Oral Presentations of Selected Abstracts (Non-CME)

Chairs: Alanna Morris, MD (Emory), Rami Alharethi, MD (Intermountain), Dipayan Chaudhuri, MD/PhD (U of U CVRTI) and Matt Goodwin, MD (U of U)

1. Lack of cardiac p62/Sqstm1 precipitates cardiac aging via impaired NRF2 signaling. Rajeshwary Ghosh, University of Utah
2. Cannabidiol loaded nanoparticles for the treatment of non-ischemic heart failure. Muthu Krishnamoorthi, Houston Methodist Hospital
3. A hepato-cardiac FGF21 axis activates a cardiac FGF21 autocrine mechanism that drives hypertrophy during pressure overload. Sobuj Mia, University of Cincinnati
4. Simultaneous Impella unloading with reperfusion after acute myocardial infarction increases myocardial salvage in swine. Joe Visker, University of Utah
5. Clonal haematopoiesis is associated with higher mortality in patients with cardiogenic shock. Fernando L Scolari, U of Toronto, Canada
6. In vitro and in vivo hemodynamic testing of the pulsatile CorWave membrane LVAD. Trevor Snyder, CorWave SA, Clichy, France
7. Machine learning identification of transcriptomics and clinical characteristics associated with myocardial recovery in heart failure patients undergoing mechanical circulatory support. Christos P. Kyriakopoulos, University of Utah
8. Variation in hemodynamics among heart failure patients supported by continuous-flow LVAD - a pilot study. Nikhil Shamapant, University of Colorado
9. Cardiac ventricular fibrosis in patients with advanced biventricular heart failure undergoing durable mechanical circulatory support. Michael Bonios, Onassis Cardiac Surgery Center, Athens, Greece
10. Repetitive milrinone therapy in ambulatory advanced heart failure patients. Ofer Havakuk, Tel Aviv Medical Center, Israel
11. Myocardial recovery and VAD explantation in the pediatric population: an analysis of the ACTION registry. Beth Hawkins, Boston Children's Hospital
12. Outcomes after durable LVAD explantation in patients with non-ischemic cardiomyopathy with evidence of cardiac recovery, including Indications for urgent device decommissioning. Zachary J. Il'Giovine, Cleveland Clinic, Ohio

2.00-2.15pm Break

2.15-4.15pm

View Session 5 - 6 recordings HERE

Session 5: Clinical Cardiac Recovery and Remission in Chronic HF Patients

Chairs: Jane Farr, MD, (UTSW), Angela Lorts, MD, (Cincinnati Children’s) and Jan Schmitto, MD/PhD (Hannover, Germany)

1. Innovative approaches in the Berlin Myocardial Recovery Program. Jan Knierim, MD, Berlin Heart Institute, Germany
2. Resilience and myocardial recovery in children. Iki Adachi, MD, Texas Children’s/Baylor
3. Reverse cardiac remodeling following MCS: the case for hemodynamic monitoring. Palak Shah, MD, Inova
4. High risk percutaneous mitral and aortic valve interventions facilitated by mechanical circulatory support.  William O’Neill, MD, Henry Ford 

(20 min talks + 10min discussion each) 

4.15-6.15pm

Session 6: Diagnostic and Therapeutic Recovery Strategies in Acute HF and Shock

Chairs: Mariell Jessup, MD (AHA), Shelley Hall, MD (Baylor Dallas) and Navin Kapur, MD (Tufts)

1. Therapeutic dilemmas in acute HF and shock post UNOS organ allocation changes. Veli Topkara, MD, Columbia
2. Debate: PA line-derived hemodynamics to guide cardiogenic shock management in the ICU.

Pro: Adriana Luk, MD, University of Toronto, Canada (15min and 5min rebuttal)

Con: Erin Bohula, MD, DPhil, Brigham and Women’s, Boston (15min and 5min rebuttal)

Discussion: 10 min

3. Debate: LV venting is required during VA-ECMO to prevent increases in myocardial afterload, oxygen consumption and energy expenditure.

Pro: Daniel Burkhoff, MD/PhD, Columbia and CRF (15min and 5min rebuttal)

Con: Demetris Yannopoulos, MD, U of Minnesota (15min and 5min rebuttal)

Discussion: 10 min